Please login to the form below

Not currently logged in

Millennium expands Velcade tests

Millennium Pharmaceuticals begins tests to evaluate its blood cancer drug Velcade in combination with other drugs

Millennium Pharmaceuticals has begun tests to evaluate its blood cancer drug Velcade (bortezomib) in combination with other drugs.

Velcade, which Millennium is developing with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), can be prescribed to patients with multiple myeloma who have received at least one prior therapy.

The phase II trial will evaluate the efficacy of combining Velcade for injection with lenalidomide, dexamethasone and cyclophosphamide in the front-line multiple myeloma setting.

In a press statement, Millennium's CMO Nancy Simonian, said: "The objective of this trial is to evolve the treatment of multiple myeloma by combining these highly active therapies to induce early complete remission and improve long term survival."

16th August 2007


Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....